References
- Godeau B, Bierling P. Treatment of idiopathic thrombocytopenic purpura in adults. Presse Med 2008; 37: 1292–1298.
- Arnold DM, Dentali F, Crowther MA et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007; 146: 25–33.
- Schweizer C, Reu FJ, Ho AD, Hensel M. Low rate of long-lastingremissions after successful treatment of immune thrombocytopenic purpura with rituximab. Ann Hematol 2007; 86: 711–717.
- Braendstrup P, Bjerrum OW, Nielsen OJ et al. Rituximab chimericanti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol 2005; 78: 275–280.
- Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001; 98: 952–957.
- Thou Z, Yang R. Rituximab treatment for chronic refractory idiopathic thrombocytopenic purpura. Grit Rev Oncol Hematol 2008; 65: 21–31.
- Hou M, Peng J, Shi Y et al. Mycophenolate mofetil (MMF) for thetreatment of steroid-resistant idiopathic thrombocytopenic pur-pura. Eur J Haematol 2003; 70: 353–357.
- Provan D, Moss AJ, Newland AC, Bussel JB. Efficacy of mycophenolate mofetil for refractory immune thrombocytopenic purpura. Am J Hematol 2006; 81: 19–25.
- Kotb R, Pinganaud C, Trichet C et al. Efficacy of mycophenolatemofetil in adult refractory auto-immune cytopenias: a single center preliminary study. Eur J Haematol 2005; 75: 60–64.
- Zhang W, Ji L, Cao X et al. Mycophenolate mofetil as a treatment for refractory idiopathic thrombocytopenic purpura. APS 2005; 26: 598–602.